Revenue base centered on research support services
First written in FY2020-Q1. 12 of 22 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Update to Revenue CompositionAnnual report
「At present, the research support business accounts for approximately 87% of sales. The company will continue to promote it globally as a core business in the short to medium term.」
Updated the research support business's share of total sales to approximately 87%, while maintaining its positioning as a core business and earnings base in the short to medium term, to be promoted globally. - FY2026-H1RestatedAnnual report
「The research support business is building a short- to medium-term earnings base, centered on applying iPS cells to elucidating disease mechanisms and drug discovery research.」
The company has reconfirmed its policy of positioning the research support business as a short- to medium-term earnings base and securing revenue through products and services for research use. - FY2025Update to Revenue CompositionAnnual report
「At present, the research support business accounts for approximately 81% of sales.」
Updated the research support business's share of total sales to approximately 81%, while maintaining its positioning as a core business and earnings base in the short to medium term, to be promoted globally. - FY2024Update to Revenue CompositionAnnual report
「At present, the research support business accounts for approximately 86% of sales. The company will continue to promote it globally as a core business in the short to medium term.」
Updated the research support business's share of total sales from approximately 68% in the previous fiscal year to approximately 86%, reconfirming its position as a short- to medium-term earnings base. - FY2024-Q3RestatedAnnual report
「Because the products are intended for research use, marketing authorization like that required for pharmaceuticals is not needed, enabling new technologies to be commercialized and monetized in a relatively short period. The company has a broad "human cell business platform" centered on iPS cells and is rolling out highly competitive products and services worldwide, positioning the business as a short- to medium-term earnings pillar.」
The company has reconfirmed its policy of positioning the research support business as a short- to medium-term earnings base that can be commercialized and monetized in a relatively short period. - FY2024-Q2RestatedAnnual report
「Because the products are intended for research use, marketing authorization like that required for pharmaceuticals is not needed, enabling new technologies to be commercialized and monetized in a relatively short period. The company has a broad "human cell business platform" centered on iPS cells and is rolling out highly competitive products and services worldwide, positioning the business as a short- to medium-term earnings pillar.」
The company has reconfirmed its policy of positioning the research support business as a short- to medium-term earnings base that can be commercialized and monetized in a relatively short period. - FY2024-Q1RestatedAnnual report
「Because the products are intended for research use, marketing authorization like that required for pharmaceuticals is not needed, enabling new technologies to be commercialized and monetized in a relatively short period. The company has a broad "human cell business platform" centered on iPS cells and is rolling out highly competitive products and services worldwide, positioning the business as a short- to medium-term earnings pillar.」
The company has reconfirmed its policy of positioning the research support business as a short- to medium-term earnings base that can be commercialized and monetized in a relatively short period. - FY2023Update to Revenue CompositionAnnual report
「At present, the research support business accounts for approximately 68% of sales. The company will continue to promote it globally as a core business in the short to medium term.」
Updated the research support business's share of total sales to approximately 68%. Its positioning as a core business and earnings base in the short to medium term, to be promoted globally, remains unchanged. - FY2023-Q3RestatedAnnual report
「Because the products are intended for research use, marketing authorization like that required for pharmaceuticals is not needed, enabling new technologies to be commercialized and monetized in a relatively short period. The company has a broad "human cell business platform" centered on iPS cells and is rolling out highly competitive products and services worldwide, positioning the business as a short- to medium-term earnings pillar.」
The company has reconfirmed its policy of positioning the research support business as a short- to medium-term earnings base that can be commercialized and monetized in a relatively short period. - FY2023-Q2Update to the sales mix benchmarkAnnual report
「Because the products are intended for research use, marketing authorization like that required for pharmaceuticals is not needed, enabling new technologies to be commercialized and monetized in a relatively short period. In the previous fiscal year, the research support business accounted for approximately 60% of total sales.」
The filing states that the research support business accounted for approximately 60% of sales in the "previous fiscal year." Its positioning as a short- to medium-term earnings pillar remains unchanged. - FY2023-Q1Update to Revenue CompositionAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for approximately 70% of total revenue.」
Updated the research support business's share of total sales from the previously stated 60% or more to approximately 70%, while maintaining its position as a short- to medium-term earnings base. - FY2022-Q3RestatedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 60% of total revenue.」
The company has reaffirmed that the research support business forms a revenue base over the short to medium term, accounting for more than 60% of revenue. - FY2022-Q2Update to Revenue CompositionAnnual report
「At present, revenue from the research support business accounts for more than 60% of total revenue.」
The research support business's share of revenue was updated from more than 90% to more than 60%. Its position as a business to be expanded globally as a core source of revenue over the short to medium term remains unchanged. - FY2022-Q1Update to Revenue CompositionAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 70% of total revenue.」
The company updated the research support business's share of revenue from more than 90% to more than 70%. Its position as a core source of revenue over the short to medium term remains unchanged. - FY2021RestatedAnnual report
「At present, revenue from the research support business accounts for more than 90% of total revenue, and the company will continue promoting it globally as a core business over the short to medium term.」
The company has reaffirmed that the research support business forms a revenue base over the short to medium term, accounting for more than 90% of revenue. - FY2021-Q3RestatedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 90% of total revenue.」
The company has reaffirmed that the research support business is relatively easy to commercialize and monetize within a short period and forms a revenue base over the short to medium term, accounting for more than 90% of revenue. - FY2021-Q2RestatedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 90% of total revenue.」
The company has reaffirmed that the research support business is relatively easy to commercialize and monetize within a short period and forms a revenue base over the short to medium term, accounting for more than 90% of revenue. - FY2021-Q1RestatedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 90% of total revenue.」
The company has reaffirmed that the research support business is easy to commercialize and monetize within a short period and forms a revenue base over the short to medium term, accounting for more than 90% of revenue. - FY2020Update to Revenue CompositionAnnual report
「At present, revenue from the research support business accounts for more than 90% of total revenue, and the company will continue promoting it globally as a core business over the short to medium term.」
The company updated the research support business's share of revenue from more than 80% to more than 90% and reaffirmed its position as a core source of revenue over the short to medium term. - FY2020-Q3RestatedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 80% of total revenue.」
The company has reaffirmed that the research support business is relatively easy to commercialize and monetize within a short period and accounts for more than 80% of revenue. - FY2020-Q2RestatedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 80% of total revenue.」
The company has reaffirmed that the research support business is relatively easy to commercialize and monetize within a short period and accounts for more than 80% of revenue. - FY2020-Q1First statedAnnual report
「Because the business is for research use, marketing authorization such as that required for pharmaceuticals is not necessary, which enables new technologies to be commercialized and generate revenue in a relatively short period. At present, revenue from the research support business accounts for more than 80% of total revenue.」
The company first explicitly stated that the research support business is positioned as a business that can be commercialized and monetized in a relatively short period and accounts for more than 80% of current revenue.